Acute Myeloid Leukemia Clinical Trial
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Summary
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Eligibility Criteria
Inclusion Criteria Patient
Patient with a clinical suspicion for a new diagnosis of AML or MDS for whom the diagnostic molecular testing via the hematologic molecular algorithm (HMA) at BJH is requested or planned to be requested.
Adult patients 18 years or older.
Ability to understand and willingness to sign an IRB approved written informed consent document.
Inclusion Criteria Physician
Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
Able and willing to complete standardized questionnaires about usability, and stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process.
Exclusion Criteria Patient
Younger than 18 years of age
Exclusion Criteria Physician
Does not treat patients at Washington University School of Medicine
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Saint Louis Missouri, 63110, United States More Info
Principal Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
How clear is this clinincal trial information?